| Document |
Document Title |
|
JP4889986B2 |
To provide a promoter for DHEA (dehydroepiandrosterone) effects, capable of increasing DHEA effects to prevent aging, and opening the way to treatment of several diseases by effects of antiarteriosclerosis, antiobesity, muscular dystroph...
|
|
JP4889644B2 |
The invention provides 15β-substituted steroidal compounds having selective estrogen receptor activity according to Formula I: wherein, R1 is H, C1-5 alkyl, C1-12 acyl, di-(C1-5 alkyl)aminocarbonyl, (C1-5alkyl)oxycarbonyl or sulfamoyl, ...
|
|
JP4883542B2 |
Hormonal pharmaceutical compositions for oral administration contain an oestrogenic compound (I) and a progestational compound (II), together with inert excipients.
|
|
JP4866740B2 |
Compounds having the structure or their salts: are used to treat or reduce le likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, sebor...
|
|
JP4860880B2 |
The invention relates to novel 8ß-substituted estratrienes of the general formula (I), wherein R2, R3, R6, R6', R7, R7', R9, R11, R11', R12, R14, R15, R15', R16, R16', R17 and R17' are defined as in the description and R8 represents a s...
|
|
JP4851057B2 |
Use of an oestrogen in the manufacture of a composition containing oestrogen for the treatment of atrophic vaginits, in woman by administering weekly an amount of about 10 to 30 ug estradiol to a woman
|
|
JP4845320B2 |
Methods of using 7alpha,11beta-dimethyl-17beta-hydroxyestra-4,14-dien-3-one (III)
|
|
JP4843261B2 |
|
|
JP2011529485A |
The present invention is related to a use of a steroid sulfatase inhibitor in the manufacture of a medicament for preventing or inhibiting premature uterine contractions. Specifically, the present invention is related to steroid sulfatas...
|
|
JP4824223B2 |
|
|
JP2011527302A |
Use of 9±-estra-1,3,5(10)-triene derivatives of formula (I) for the prevention and treatment of intestinal cancer, in particular adenoma and adenocarcinoma of the duodenum, ileum, colon, and rectum.
|
|
JP4801868B2 |
|
|
JP4798924B2 |
|
|
JP4796693B2 |
The present invention provides in one aspect, a novel method for recovering an organic solute from a predominantly aqueous solution. In one embodiment, the solution is contacted with a dry, non-conditioned sorbent medium held by a suppor...
|
|
JP4778438B2 |
The present invention relates to novel 3, 15 substituted estrone derivatives which represent inhibitory compounds of the 17beta-hydroxysteroid dehydrogenase type I (17beta-HSD1), to their salts, to pharmaceutical preparations containing ...
|
|
JP4755083B2 |
The subject of the invention is a method for preparing compounds of general formula (I): in which A, Z, R3 are as defined in the description, and the intermediate compounds for carrying out this method.
|
|
JP2011148821A |
To provide a novel method for preparing a cortisol conjugate.The method for preparing the cortisol conjugate includes reacting 3-cortisolcarboxymethyl oxime conjugated to bovine serum albumin (3-CMO-BSA) with sodium borohydride.
|
|
JP2011521005A |
Novel benzoic acid hydrazones of 5alpha-androstan-3,17-dione have been prepared on the basis of steroidal tigogenin of the plant Yucca gloriosa. The hydrazones of the General Formula (I), General Formula (II) and General Formula (III) as...
|
|
JP2011520820A |
Pharmaceutical combination preparation comprises single dose units of the progesterone receptor antagonists of 20,20,21,21,21-pentafluoro-17-hydroxy-11beta -[4-(hydroxyacetyl)phenyl]-19-nor-17alpha -pregna-4,9-dien-3-one (I) and individu...
|
|
JP4719144B2 |
The present invention provides a compound comprising a steroidal ring system and an optional group R1 selected from any one of —OH, a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide ...
|
|
JP4716726B2 |
The subject invention provides new progestogen esters and uses thereof.
|
|
JP4709751B2 |
A process for preparing a compound of formula (I): wherein X represents O or S; R 1 represents C 1-6 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkylmethyl or C 3-8 cycloalkenyl any of which optionally may be substituted by one or more methyl g...
|
|
JP4709752B2 |
A process for preparing a compound of formula (I): wherein X represents O or S; R 1 represents C 1-6 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkylmethyl or C 3-8 cycloalkenyl any of which optionally may be substituted by one or more methyl g...
|
|
JP4698773B2 |
The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and...
|
|
JP4691028B2 |
A method for obtaining an extract containing the natural mixture of conjugated equine estrogens in which a mixture of conjugated estrogens obtained by solid-phase extraction from pregnant mares' urine is depleted in phenolic urine conten...
|
|
JP2011093929A |
To provide a new compound which is an androstane-type glucocorticoid receptor agonist.The compound is expressed by formula (I) (in the formula, X is O or S; R1 is 1-6C alkyl, 3-8C cycloalkyl, 3-8C cycloalkylmethyl, 3-8C cycloalkenyl or t...
|
|
JP4680891B2 |
The present invention relates to pharmaceutical compositions, formulated for injectable administration, which comprises a testosterone ester, in particularly testosterone undecanoate, in a vehicle comprising castor oil and a co-solvent. ...
|
|
JP2011511011A |
The invention provides and describes solid state 17α-ethynyl-5α-androstane-3α,17β-diol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-5α-androstane-3α,17β-...
|
|
JP4651341B2 |
|
|
JP2011506405A |
6-alkylidenandrost-1,4-dien-3-ones of general formula (I), wherein R is H o alkyl; R 1 y R 2 , independently of one another, represent H, OR 3 , OC(=O) R 4 or O-(GPH), wherein R 3 is H; C 1 -C 6 alkyl or aryl; R 4 is H or C 1 -C 6 alkyl,...
|
|
JP2011506368A |
Copper-bromide mediated aromatization of 19-nor-androst-4-en-3-one compounds (II) to estra-1,3,5(10)-triene compounds (I) and their enantiomers or diastereomers in the presence of at least an electron-rich unsaturated organic additive (I...
|
|
JP4629030B2 |
The invention relates to a process for preparing compounds of formula (I): in which R1, R2, R3, n and X are as defined in the description, and to the intermediate compounds for implementing this process.
|
|
JP2011503129A |
The present invention relates to novel uses of C-19 steroid compounds, in particular C-19 steroids having an androsten-17-(OR 4 )-3-one structure for cosmetic and further uses, wherein R 4 is hydrogen or an unsubstituted or substituted a...
|
|
JP4613366B2 |
The present invention relates to new compounds represented by Formula I: wherein M represents a macrolide subunit of the substructure II: L represents the chain of the substructure III: -X 1 -(CH 2 ) m -Q...
|
|
JP4615998B2 |
The invention relates to novel 9 alpha -substituted estratrienes of general formula (I) - wherein R3, R7, R7', R13, R16, R17 and R17' have the designations cited in the description, and R9 represents a linear-chain or branched-chain, opt...
|
|
JP2011500738A |
TRPC ion channels are non-selective channels widely expressed in human tissues. These channels are involved in numerous physiological functions and are putative targets for the development of novel medicines. There is a need to gain a be...
|
|
JP2011500740A |
11 beta -Fluoro-3-acetoxyestra-3,5-dien-17-one (I), is new. An independent claim is included for the preparation of (I). ACTIVITY : None given. MECHANISM OF ACTION : None given.
|
|
JP2010536910A |
The present invention relates to a new process for preparing estrogen-antagonistic 11²-fluoro-17±-alkylestra-1,3,5(10)-triene-3,17-diols of the general formula I having a 7±-(¾-alkylamino-É-perfluoroalkyl)alkyl side chain and to ±-...
|
|
JPWO2009022477A1 |
To provide a polymer polymer in which a physiologically active substance is uniformly distributed at a high density. The above problem can be solved by selecting and using polynorbornene as a polymer polymer. [Selection diagram] None
|
|
JP2010533152A |
The invention refers to 8²-substituted estra-1,3,5(10)-triene derivatives of general formula I their use as pharmaceutical active ingredients, which have in vitro a higher affinity to estrogen receptor preparations from rat prostates th...
|
|
JP4564920B2 |
An agent for treating cataract which contains sexual steroid hormone such as estrogen or its metabolites, its derivative, structural analogues thereof, estrogen acting substance or SERM or non-feminizing estrogen (non-hormonal estrogen) ...
|
|
JP4553586B2 |
There is provided a compound having Formula (I) wherein G is H or a substituent, and wherein R<1> is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group, capable of inhi...
|
|
JP4553166B2 |
PCT No. PCT/GB96/01054 Sec. 371 Date Mar. 3, 1998 Sec. 102(e) Date Mar. 3, 1998 PCT Filed May 1, 1996 PCT Pub. No. WO96/34858 PCT Pub. Date Nov. 7, 1996Compounds, compositions, and methods of use as a pharmaceutical, where the compounds ...
|
|
JP2010531305A |
New crystalline polymorph of exemestane characterized by a powder X-ray diffraction pattern having peaks at 10.7±0.1, 15.9±0.1, and 18.1±0.1 2-theta degree.
|
|
JP2010530876A |
Synthesis of deoxycholic acid (DCA) comprising reducing compound 11 to compound 12 and further deprotecting compound 12.
|
|
JP4546596B2 |
Stearin ester derivatives (I) are used in biological solutions for long term stabilization. Stearin ester derivatives of formula (I) are used in biological solutions for long term stabilization. n = 1-200; R1 = stearin; and R2 = 4-8C ali...
|
|
JP4545929B2 |
The invention is directed to a novel class of steroids which exhibit potent antiprogestational activity.
|
|
JP4541698B2 |
3-Hydroxy-7-hydroxy steroids and 3-oxo-7-hydroxy steroids, especially the 7β-isomers thereof, and pharmaceutically acceptable esters thereof are useful for protection against ischaemia-induced damage to peripheral organs, such as the he...
|
|
JP2010189409A |
To provide an estradiol composition which has no generalized absorption of estradiol or slight generalized absorption, improves a vaginal mucous membrane, provides atrophy vaginal epithelium with a positive effect, reduces the risk of os...
|
|
JP2010524997A |
The present invention relates to the single use of the progesterone-receptor antagonist 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2,2-pe
ntafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or anal...
|
